MedTrace Logo

Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus

NCT05043467 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2228

Last updated 2021-09-14

No results posted yet for this study

Summary

Previous thiazolidinediones (TZDs) have issued various safety concerns including weight gain, bladder cancer, and congestive heart failure (CHF). This study aimed to evaluate the efficacy and safety of lobeglitazone, a novel TZD in patients with type 2 diabetes in real world.

Conditions

  • Type2 Diabetes

Interventions

DRUG

Duvie(Lobeglitazone) tab 0.5mg

patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Sung-Rae S Kim, M.D, PhD · Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St Mary's Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-02
Primary Completion
2020-06-19
Completion
2020-06-19

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043467 on ClinicalTrials.gov